Comparative Pharmacology
Head-to-head clinical analysis: ANSOLYSEN versus FENOLDOPAM MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSOLYSEN versus FENOLDOPAM MESYLATE.
ANSOLYSEN vs FENOLDOPAM MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 24-48 hours in renal impairment, necessitating dose adjustment.
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Renal excretion predominates (approximately 70-80% as unchanged drug via glomerular filtration; remainder as metabolites). Biliary/fecal elimination accounts for <10%.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Category C
Category C
Antihypertensive
Antihypertensive